CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA)

ClinicalTrials.gov ID

NCT07645755

Lead Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

50Estimated

Last Update Posted

Jun 12, 2026Actual

Start Date

Jul 15, 2026Estimated

Primary Completion Date

Jul 31, 2027Estimated

Completion Date

Dec 31, 2027Estimated

Official Title

Evaluation of Response to Clopidogrel in Patients With Essential Thrombocythemia

Brief Summary

Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm associated with increased platelet production and activation, leading to a high risk of thrombotic complications. Low-dose aspirin is the standard antiplatelet therapy for thrombosis prevention; however, the accelerated platelet turnover characteristic of ET results in rapid recovery of platelet function, making once-daily aspirin insufficient in many patients. Consequently, twice-daily low-dose aspirin is currently recommended to achieve adequate and sustained platelet inhibition.

For patients intolerant to aspirin, clopidogrel 75 mg/day is the approved alternative. Clopidogrel irreversibly inhibits the platelet P2Y12 receptor, but its pharmacodynamic effect is highly variable because it is a prodrug requiring metabolic activation. Studies in non-ET populations have shown that higher clopidogrel doses (150 mg/day) provide stronger and more consistent platelet inhibition without significantly increasing bleeding risk.

Evidence on clopidogrel use in ET is limited, but available data suggest that standard-dose therapy may result in inadequate platelet inhibition, potentially reducing antithrombotic efficacy. Platelet function testing can identify patients with high residual platelet reactivity ("poor responders"), who may benefit from dose escalation. Therefore, in ET patients requiring clopidogrel therapy, assessment of platelet responsiveness may help optimize treatment, ensuring adequate platelet inhibition and potentially improving protection against thrombotic events.

• Essential Thrombocythemia

• VerifyNow P2Y12 assay

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Male or female subjects age ≥ 18 years;
2. Confirmed diagnosis of ET according to the 2022 WHO classification criteria30;
3. Patients treated with clopidogrel 75 mg od as antithrombotic prophylaxis since at least 3 weeks, as per the indication of the referring hematologist;
4. Ability to understand the nature of the study and voluntarily provide written informed consent patients whose responsiveness to the standard clopidogrel regimen was determined, based on clinical practice, using the VN-P2Y12 method.

Exclusion Criteria:

1. Platelet count >1,000,000/μL on three separate determinations within the 2 months prior to enrollment;
2. Need for anticoagulant therapy;
3. Concomitant use of other antiplatelet agents;
4. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) (i.e > 3 days per week);
5. Chronic corticosteroid therapy exceeding a daily dose equivalent to prednisone 5 mg

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER

ebeggiato@cittadellasalute.to.it

• Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI

  NCT00517478

  Unknown statusObservationalUpdated Aug 17, 2007
• Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis

  NCT01511471

  CompletedInterventionalPhase 3Updated Feb 3, 2012
• High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures

  NCT01744613

  CompletedObservationalUpdated Jan 14, 2013
• Clopidogrel and Response Variability Investigation Study 2

  NCT00822666

  CompletedInterventionalPhase 3Updated Dec 11, 2012
• Platelet Reactivity in Stent Thrombosis Patients

  NCT01012544

  CompletedInterventionalPhase 4Updated Aug 23, 2011
• Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance

  NCT00697021

  Unknown statusInterventionalPhase 3Updated Jun 13, 2008